Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Melanocortin Receptor 4 (MC4R) - Overview
Melanocortin Receptor 4 (MC4R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
Eton Pharmaceuticals Inc
LG Chem Ltd
Mallinckrodt Plc
Palatin Technologies Inc
Pfizer Inc
Rhythm Pharmaceuticals Inc
Melanocortin Receptor 4 (MC4R) - Drug Profiles
bremelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-54640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LR-19021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-07258669 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-9610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize MC4-R for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocortin Receptor 4 (MC4R) - Dormant Products
Melanocortin Receptor 4 (MC4R) - Discontinued Products
Melanocortin Receptor 4 (MC4R) - Product Development Milestones
Featured News & Press Releases
Jul 01, 2021: Mallinckrodt announces inclusion of Acthar Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) treatment guidelines for patients with pulmory sarcoidosis
Jun 24, 2021: PANTHERx Rare Pharmacy selected by Rhythm Pharmaceuticals to distribute IMCIVREE (setmelanotide) for chronic weight magement in patients with obesity due to POMC, PCSK1 or LEPR deficiency
May 21, 2021: Rhythm Pharmaceuticals receives positive CHMP opinion for Setmelanotide for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiency
May 19, 2021: Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
May 04, 2021: Palatin announces U.S. patent term extension for Vyleesi (bremelanotide injection)
May 03, 2021: Mallinckrodt presents data evaluating Acthar Gel (Repository Corticotropin Injection) for the treatment of severe keratitis at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting
Mar 20, 2021: Rhythm Pharmaceuticals presents new data from phase 2 basket study showing continued weight loss at up to nine months in patients with HET obesity on Setmelanotide at ENDO 2021
Mar 09, 2021: Rhythm Pharmaceuticals announces late-breaking data presentations at ENDO 2021
Jan 26, 2021: Rhythm Pharmaceuticals announces positive data with setmelanotide in additiol MC4R pathway deficiency-related obesities
Jan 19, 2021: Rhythm Pharmaceuticals to provide update on phase 2 basket study and genetic sequencing efforts
Dec 22, 2020: Rhythm Pharmaceuticals announces positive topline results from pivotal Phase 3 clinical trial evaluating Setmelanotide in Bardet-Biedl and Alstrom Syndromes
Nov 27, 2020: Rhythm Pharmaceuticals announces FDA approval of IMCIVREE (setmelanotide) as first-ever therapy for chronic weight magement in patients with obesity due to POMC, PCSK1 or LEPR Deficiency
Nov 04, 2020: Rhythm Pharmaceuticals announces new clinical data on setmelanotide at ObesityWeek 2020
Oct 30, 2020: Rhythm Pharmaceuticals announces publication of results from phase 3 clinical trials of setmelanotide in The Lancet Diabetes & Endocrinology
Oct 20, 2020: City of Rockford $10 billion lawsuit against pharmaceutical giant Mallinckrodt threatened by bankruptcy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Eton Pharmaceuticals Inc, 2021
Pipeline by LG Chem Ltd, 2021
Pipeline by Mallinckrodt Plc, 2021
Pipeline by Palatin Technologies Inc, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Rhythm Pharmaceuticals Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021